Michael E Menefee MD

Oncology•Cleveland, OH

Endocrine Cancer, Thoracic Cancer

Cleveland Clinic

Join to View Full Profile

9500 Euclid AveCA-60Cleveland, OH 44195
Phone+1 216-445-7920
Fax+1 216-444-9464

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Meharry Medical CollegeClass of 1999

Certifications & Licensure

MD State Medical License 2004 - 2025
OH State Medical License 2023 - 2025
DC State Medical License 2021 - 2024
FL State Medical License 2000 - 2022
GA State Medical License 2014 - 2017
MN State Medical License 2006 - 2007
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Feb 01
Completed
Phase 2
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Start of enrollment: 2009 Nov 03
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Mar 25
ACTIVE_NOT_RECRUITING
PHASE1
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2011 Jun 27
ACTIVE_NOT_RECRUITING
PHASE1
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 01
Withdrawn
Phase 1
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function Start of enrollment: 2011 Oct 01
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2013 Aug 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid
Investigational New Drugs. 2021-09-13
17 citations
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Keith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples
Thyroid. 2020-09-08
11 citations
Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
Nicole M. Iñiguez-Ariza, Sina Jasim, Mabel Ryder, Ashish V. Chintakuntlawar, John C. Morris
The Journal of Clinical Endocrinology and Metabolism. 2020-07-01

Lectures

Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.
2019 ASCO Annual Meeting - 6/1/2019